Comparison of high flow nasal cannula oxygen and conventional oxygen therapy on ventilatory support duration during acute-on-chronic respiratory failure: study protocol of a multicentre, randomised, controlled trial. The 'HIGH-FLOW ACRF' study

Jean-Damien Ricard, Fadia Dib, Marina Esposito-Farese, Jonathan Messika, Christophe Girault, REVA network, Stephan Ehrmann, Alain Mercat, Alexandre Demoule, Muriel Fartoukh, Benjamin Sztrymf, Jack Richecoeur, Claude Guerin, Jean Reignier, Saad Nseir, Arnaud W Thille, Erwanl 'her, Thierry Boulain, Jean-Philippe Rigaud, Antoine Cuvelier, Kaldoun Kuteifan, Sandrine Jaffré, Armand Mekontso Dessap, Jean-Christophe Callahan, Jean-Claude Lacherade, Jean-Michel Constantin, Gilles Capellier, Emmanuel Antok, Sarah Heili, Lise Piquilloud, Jean-Damien Ricard, Fadia Dib, Marina Esposito-Farese, Jonathan Messika, Christophe Girault, REVA network, Stephan Ehrmann, Alain Mercat, Alexandre Demoule, Muriel Fartoukh, Benjamin Sztrymf, Jack Richecoeur, Claude Guerin, Jean Reignier, Saad Nseir, Arnaud W Thille, Erwanl 'her, Thierry Boulain, Jean-Philippe Rigaud, Antoine Cuvelier, Kaldoun Kuteifan, Sandrine Jaffré, Armand Mekontso Dessap, Jean-Christophe Callahan, Jean-Claude Lacherade, Jean-Michel Constantin, Gilles Capellier, Emmanuel Antok, Sarah Heili, Lise Piquilloud

Abstract

Introduction: This study protocol describes a trial designed to investigate whether high-flow heated and humidified nasal oxygen (HFHO) therapy in patients with hypercapnic acute respiratory failure (ARF) reduces the need of non-invasive ventilation (NIV).

Methods and analysis: This is an open-label, superiority, international, parallel-group, multicentre randomised controlled two-arm trial, with an internal feasibility pilot phase. 242 patients with hypercapnic ARF requiring NIV admitted to an intensive care unit, an intermediate care or a respiratory care unit will be randomised in a 1:1 ratio to receive HFHO or standard oxygen in between NIV sessions. Randomisation will be centralised and stratified by centre and pH at admission (pH ≤7.25 or >7.25). The primary outcome will be the number of ventilator-free days (VFDs) and alive at day 28 postrandomisation. The secondary outcomes will encompass parameters related to the VFDs, comfort and tolerance variables, hospital length of stay and mortality. VFDs at 28 days postrandomisation will be compared between the two groups by Wilcoxon-Mann-Whitney two-sample rank-sum test in the intention-to-treat population. A sensitivity analysis will be conducted in the population of patients for whom the criteria of switching from NIV to spontaneous breathing, or conversely, are not strictly verified.

Ethics and dissemination: The protocol has been approved by the Comité de Protection des Personnes (CPP) Sud-Ouest & Outre-Mer IV (ref CPP17-049a/2017-A01830-53) and will be carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. A trial steering committee will oversee the progress of the study. Findings will be disseminated through national and international scientific conferences, and publication in peer-reviewed journals.

Trial registration number: NCT03406572.

Keywords: acute respiratory failure; chronic obstructive pulmonary disease; hypercapnia; non-invasive ventilation; oxygenation; tolerance.

Conflict of interest statement

Competing interests: J-DR, JM and CG had travel and accommodation expenses to attend scientific meetings covered by Fisher & Paykel.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Ventilatory strategy for the first sequences of NIV and SB (HFHO or standard O2), according to respective predefined criteria. Patients will follow this cycle according to their allocated group, until weaning from NIV and subsequently from oxygen therapy. ABG, arterial blood gas; HFHO, high flow heated and humidified nasal oxygen; NIV, non-invasive ventilation; SB, spontaneous breathing.

References

    1. Ford ES, Croft JB, Mannino DM, et al. . COPD surveillance--United States, 1999-2011. Chest 2013;144:284–305. 10.1378/chest.13-0809
    1. Davidson AC, Banham S, Elliott M, et al. . BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax 2016;71:ii1–ii35. 10.1136/thoraxjnl-2015-208209
    1. Schnell D, Timsit JF, Darmon M, et al. . Noninvasive mechanical ventilation in acute respiratory failure: trends in use and outcomes. Intensive Care Med 2014;40:582–91. 10.1007/s00134-014-3222-y
    1. Demoule A, Chevret S, Carlucci A, et al. . Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. Intensive Care Med 2016;42:82–92. 10.1007/s00134-015-4087-4
    1. Frat JP, Thille AW, Mercat A, et al. . High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372:2185–96. 10.1056/NEJMoa1503326
    1. Spoletini G, Alotaibi M, Blasi F, et al. . Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest 2015;148:253–61. 10.1378/chest.14-2871
    1. Chan AW, Tetzlaff JM, Altman DG, et al. . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200 10.7326/0003-4819-158-3-201302050-00583
    1. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002;30:1772–7. 10.1097/00003246-200208000-00016
    1. Thabane L, Ma J, Chu R, et al. . A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol 2010;10:1 10.1186/1471-2288-10-1
    1. Jolliet P, Besbes L, Abroug F, et al. . An international phase iii randomised trial on the efficacy of helium/oxygen during spontaneous breathing and intermittent non-invasive ventilation for severe exacerbations of chronic obstructive pulmonary disease (the e.c.h.o.icutrial). Intensive Care Med Exp 2015;3:A422 10.1186/2197-425X-3-S1-A422
    1. Maggiore SM, Richard JC, Abroug F, et al. . A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med 2010;38:145–51. 10.1097/CCM.0b013e3181b78abe
    1. Lepere V, Messika J, La Combe B, et al. . High-flow nasal cannula oxygen supply as treatment in hypercapnic respiratory failure. Am J Emerg Med 2016;34:1914.e1–1914.e2. 10.1016/j.ajem.2016.02.020
    1. Bräunlich J, Beyer D, Mai D, et al. . Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013;85:319–25. 10.1159/000342027
    1. Bräunlich J, Seyfarth HJ, Wirtz H. Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report. Multidiscip Respir Med 2015;10:27 10.1186/s40248-015-0019-y
    1. Bräunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1077–85. 10.2147/COPD.S104616
    1. Pisani L, Fasano L, Corcione N, et al. . Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax 2017;72:373–5. 10.1136/thoraxjnl-2016-209673
    1. Fraser JF, Spooner AJ, Dunster KR, et al. . Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 2016;71:759–61. 10.1136/thoraxjnl-2015-207962
    1. Frat JP, Brugiere B, Ragot S, et al. . Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: an observational pilot study. Respir Care 2015;60:170–8. 10.4187/respcare.03075
    1. Spoletini G, Mega C, Khoja A, et al. . Better comfort and dyspnea scores with high-flow nasal cannula (HFNC) vs standard oxygen (SO) during breaks off noninvasive ventilation (NIV). European Respiratory Society 2015:OA505 10.1183/13993003.congress-2015.OA505
    1. Seo KW, Ahn JJ, Jegal Y, et al. . High-flow nasal cannula oxygen therapy for acute hypoxemic respiratory failure in patients with chronic lung disease in terms of hospital outcomes. Intensive Care Med 2018;44:387–8. 10.1007/s00134-017-5018-3

Source: PubMed

3
購読する